Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: A molecular modelling study

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 8, 2005, Pages 633-639

  Paxton, James W ^a,d   Kestell, Philip ^a   Chiang, Daniel ^a   Zhou, Shufeng ^b   Lewis, David F V ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

5, 6 dimethyl xanthenone 4 acetic acid (DMXAA); Acridine; CYP1A2; Inhibition; Molecular modelling

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ACRIDINE DERIVATIVE; AMSACRINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 1A2; ETHOXYRESORUFIN; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; LIVER MICROSOME; MOLECULAR MODEL; PROTEIN DOMAIN; SEQUENCE HOMOLOGY; STEREOSPECIFICITY;

ACRIDINES; BINDING SITES; CYTOCHROME P-450 CYP1A2; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHONES;

EID: 22644443188     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0305-1870.2005.04243.x     Document Type: Article

References (22)

1. Zhou SF, Kestell P, Baguley BC, Paxton JW. 5,6-Dimethylxanthenone-4- acetic acid (DMXAA): A new biological response modifier for cancer therapy. Invest. New Drugs 2002; 20: 281-95.
2. Zhou S, Paxton JW, Tingle MD, Kestell P. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab. Dispos. 2000; 28: 1449-56.
3. Miners JO, Valente L, Lillywhite KJ et al. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 1997; 57: 284-9.
4. Zhou S, Chin R, Kestell P, Tingle MD, Paxton JW. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by human liver microsomes. Br. J. Clin. Pharmacol. 2001; 52: 129-36.
5. Robson RA, Matthews A, Miners JO et al. Characterisation of theophylline metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 1987; 24: 293-300.
6. Smith PK, Khron R, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76-85.
7. Rewcastle GW, Kestell P, Baguley BC, Denny WA. Light-induced beakdown of flavone acetic acid and xanthenone analogues in solution. J. Natl Cancer Inst. 1990; 82: 528-9.
8. Kestell P, Paxton J, Rewcastle GW, Dunlop I, Baguley BC. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother. Pharmacol. 1999; 43: 323-30.
9. Atwell GJ, Rewcastle G, Baguley BC, Denny WA. Potential anti-tumour agents. 50. In vivo solid tumour activity of derivatives of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide. J. Med. Chem. 1987; 30: 664-9.
10. Lewis DFV, Lake BG, Dickins M, Ueng YF, Goldfarb PS. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 2003; 33: 239-54.
11. Lewis DFV, Lake BG, Dickins M, Goldfarb PS. Homology modelling of human CYP3A4 from the CYP2C5 crystallographic template: Analysis of typical CYP3A4 substrate interactions. Xenobiotica 2004; 34: 549-69.
12. Lewis DFV. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305-23.
13. Lewis DFV. Molecular modelling of human cytochrome P450-substrate interactions. Drug Metab. Rev. 2002; 34: 55-67.
14. Robertson IGC, Palmer BD, Paxton JW, Bland TJ. Metabolism of the experimental antitumour agent acridine carboxamide in the mouse. Drug Metab. Dispos. 1993; 21: 530-6.
15. Schlemper B, Siegers DJ, Paxton JW, Robertson IGC. Rat hepatocyte-mediated metabolism of the experimental antitumour agent N-[2′-(dimethylamino)ethyl]acridine-4-carboxamide. Xenobiotica 1993; 23: 361-71.
16. Schofield PC, Robertson IGC, Paxton JW et al. Metabolism of N-[2′-(dimethylamino)ethyl]-acridine-4-carboxamide (DACA) in cancer patients undergoing a phase 1 clinical trial. Cancer Chemother. Pharmacol. 1999; 44: 51-8.
17. Shoemaker DD, Cysyk RL, Gormley JJ, DeSouza JJV, Malspeis L. Metabolism of 4′-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes. Cancer Res. 1984; 44: 1939-45.
18. Lewis DFV, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today 2004; 9: 530-7.
19. Lewis DFV, Lake BG, Dickins M. Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: Molecular modelling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4. Xenobiotica 2004; 34: 501-13.
20. Fuhr U, Strobl G, Manaut F et al. Quinolone antibacterial agents: Relationship between structure and the in vivo inhibition of the human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. 1993; 43: 191-9.
21. Zhou S, Kestell P, Paxton JW. 6-Methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase. Eur. J. Drug Metab. Pharmacokinet. 2002; 27: 179-83.
22. Becquemont L, Lebot MA, Riche C et al. Use of heterologous expressed human cytochrome P4501A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101-8.